Cover
| Cover | 12 Months Ended |
| Dec. 31, 2022 | |
| Document Information [Line Items] | |
| Document Type | DEF 14A |
| Amendment Flag | false |
| Entity Information [Line Items] | |
| Entity Registrant Name | Jazz Pharmaceuticals plc |
| Entity Central Index Key | 0001232524 |
Pay vs Performance Disclosure
| Pay vs Performance Disclosure - USD ($) | 12 Months Ended | ||
| Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Pay vs Performance Disclosure [Table] | |||
| Pay vs Performance [Table Text Block] | Item 402(v) Pay versus Performance The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how the company or the compensation committee view the link between the company’s performance and NEO pay. For additional information about our pay-for-performance Executive Compensation—Compensation Discussion and Analysis” Required Tabular Disclosure of Pay versus Performance The table below reflects information regarding the compensation of our NEOs for fiscal years 2022, 2021 and 2020, as well as our financial performance for each of these fiscal years in accordance with SEC rules. The amounts set forth below under the headings “Compensation Actually Paid to PEO” and “Average Compensation Actually Paid for Non-PEO S-K. Executive Compensation—Compensation Discussion and Analysis Value of Initial Fixed $100 Based On: Year Summary PEO ($) 1 Compensation PEO($) 2 Average Non-PEO 1 Average Non-PEO 2 Total Return ($) 3 Peer Group Return($) 3 GAAP Net Income/ 4 Total 5 2022 17,325,618 26,315,005 5,035,509 7,254,180 107 114 (224,060) 3,659,374 2021 15,679,311 4,921,238 4,544,613 2,655,063 85 126 (329,668) 3,094,238 2020 12,573,300 19,597,659 4,091,303 6,145,655 111 126 238,616 2,363,567 (1) For each fiscal year, represents amount reported for our principal executive officer (PEO) and average amount reported for our non-PEO non-PEO non-PEO non-PEO (2) Amounts represent Compensation Actually Paid to our PEO and the average Compensation Actually Paid to our non-PEO year-end closing options based on a Black-Scholes option pricing model on the applicable fiscal year-end 2022 2021 2020 Adjustments PEO Average Non-PEO NEOs PEO Average Non-PEO NEOs PEO Average Non-PEO NEOs Total compensation as reported in the Summary Compensation Table (SCT) 17,325,618 5,035,509 15,679,311 4,544,613 12,573,300 4,091,303 (Deduct): Grant date fair value of awards as reported in the Stock Awards and Option Awards columns in the SCT for applicable fiscal year (FY) (14,873,643 ) (3,865,859 ) (13,414,116 ) (3,505,027 ) (10,091,856 ) (3,037,957 ) Add: ASC 718 fair value of awards granted during applicable FY that remain unvested as of applicable FY-end, determined as of applicable FY-end 18,049,908 4,691,422 9,742,948 2,802,063 17,526,705 5,048,743 Add/(deduct): ASC 718 fair value of awards granted during prior FYs that were outstanding and unvested as of applicable FY-end, determined based on change in ASC 718 fair value from prior FY-end to applicable FY-end 3,823,712 996,931 (6,252,113 ) (1,092,121 ) 1,921,083 221,269 Add/(deduct): ASC 718 fair value of awards granted during prior FYs that vested during applicable FY, determined based on change in ASC 718 fair value from prior FY-end to vesting date 1,989,410 396,177 (834,792 ) (94,465 ) (2,331,573 ) (177,703 ) Total adjustments 8,989,387 2,218,671 (10,758,073 ) (1,889,550 ) 7,024,359 2,054,352 Compensation actually paid 26,315,005 7,254,180 4,921,238 2,655,063 19,597,659 6,145,655 (3) For the relevant fiscal year, represents the cumulative Total Shareholder Return of our ordinary shares and the NASDAQ Biotechnology Index at the end of each fiscal year. In each case, assume an initial investment of $100 on December 31, 2019, and reinvestment of dividends, if any. (4) The amounts represent the GAAP net income (loss) as reported in the company’s audited financial statements for the applicable fiscal year. (5) As required by Item 402(v) of Regulation S-K, | ||
| Company Selected Measure Name | total revenues | ||
| Named Executive Officers, Footnote [Text Block] | The non-PEO non-PEO non-PEO | ||
| Peer Group Issuers, Footnote [Text Block] | For the relevant fiscal year, represents the cumulative Total Shareholder Return of our ordinary shares and the NASDAQ Biotechnology Index at the end of each fiscal year. In each case, assume an initial investment of $100 on December 31, 2019, and reinvestment of dividends, if any. | ||
| PEO Total Compensation Amount | $ 17,325,618 | $ 15,679,311 | $ 12,573,300 |
| PEO Actually Paid Compensation Amount | $ 26,315,005 | 4,921,238 | 19,597,659 |
| Adjustment To PEO Compensation, Footnote [Text Block] | (2) Amounts represent Compensation Actually Paid to our PEO and the average Compensation Actually Paid to our non-PEO year-end closing options based on a Black-Scholes option pricing model on the applicable fiscal year-end 2022 2021 2020 Adjustments PEO Average Non-PEO NEOs PEO Average Non-PEO NEOs PEO Average Non-PEO NEOs Total compensation as reported in the Summary Compensation Table (SCT) 17,325,618 5,035,509 15,679,311 4,544,613 12,573,300 4,091,303 (Deduct): Grant date fair value of awards as reported in the Stock Awards and Option Awards columns in the SCT for applicable fiscal year (FY) (14,873,643 ) (3,865,859 ) (13,414,116 ) (3,505,027 ) (10,091,856 ) (3,037,957 ) Add: ASC 718 fair value of awards granted during applicable FY that remain unvested as of applicable FY-end, determined as of applicable FY-end 18,049,908 4,691,422 9,742,948 2,802,063 17,526,705 5,048,743 Add/(deduct): ASC 718 fair value of awards granted during prior FYs that were outstanding and unvested as of applicable FY-end, determined based on change in ASC 718 fair value from prior FY-end to applicable FY-end 3,823,712 996,931 (6,252,113 ) (1,092,121 ) 1,921,083 221,269 Add/(deduct): ASC 718 fair value of awards granted during prior FYs that vested during applicable FY, determined based on change in ASC 718 fair value from prior FY-end to vesting date 1,989,410 396,177 (834,792 ) (94,465 ) (2,331,573 ) (177,703 ) Total adjustments 8,989,387 2,218,671 (10,758,073 ) (1,889,550 ) 7,024,359 2,054,352 Compensation actually paid 26,315,005 7,254,180 4,921,238 2,655,063 19,597,659 6,145,655 | ||
| Non-PEO NEO Average Total Compensation Amount | $ 5,035,509 | 4,544,613 | 4,091,303 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 7,254,180 | 2,655,063 | 6,145,655 |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | (2) Amounts represent Compensation Actually Paid to our PEO and the average Compensation Actually Paid to our non-PEO year-end closing options based on a Black-Scholes option pricing model on the applicable fiscal year-end 2022 2021 2020 Adjustments PEO Average Non-PEO NEOs PEO Average Non-PEO NEOs PEO Average Non-PEO NEOs Total compensation as reported in the Summary Compensation Table (SCT) 17,325,618 5,035,509 15,679,311 4,544,613 12,573,300 4,091,303 (Deduct): Grant date fair value of awards as reported in the Stock Awards and Option Awards columns in the SCT for applicable fiscal year (FY) (14,873,643 ) (3,865,859 ) (13,414,116 ) (3,505,027 ) (10,091,856 ) (3,037,957 ) Add: ASC 718 fair value of awards granted during applicable FY that remain unvested as of applicable FY-end, determined as of applicable FY-end 18,049,908 4,691,422 9,742,948 2,802,063 17,526,705 5,048,743 Add/(deduct): ASC 718 fair value of awards granted during prior FYs that were outstanding and unvested as of applicable FY-end, determined based on change in ASC 718 fair value from prior FY-end to applicable FY-end 3,823,712 996,931 (6,252,113 ) (1,092,121 ) 1,921,083 221,269 Add/(deduct): ASC 718 fair value of awards granted during prior FYs that vested during applicable FY, determined based on change in ASC 718 fair value from prior FY-end to vesting date 1,989,410 396,177 (834,792 ) (94,465 ) (2,331,573 ) (177,703 ) Total adjustments 8,989,387 2,218,671 (10,758,073 ) (1,889,550 ) 7,024,359 2,054,352 Compensation actually paid 26,315,005 7,254,180 4,921,238 2,655,063 19,597,659 6,145,655 | ||
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | |||
| Compensation Actually Paid vs. Net Income [Text Block] | |||
| Compensation Actually Paid vs. Company Selected Measure [Text Block] | |||
| Total Shareholder Return Vs Peer Group [Text Block] | |||
| Tabular List [Table Text Block] | The most important financial and non-financial “Executive Compensation—Compensation Discussion and Analysis” • Total Revenues • Revenue (product- / therapeutic area-specific) • Non-GAAP Adjusted Operating Margin • Relative TSR • 3 Year Revenue Compound Annual Growth Rate • Pipeline Progression • Regulatory Advancement | ||
| Total Shareholder Return Amount | $ 107 | 85 | 111 |
| Peer Group Total Shareholder Return Amount | 114 | 126 | 126 |
| Net Income (Loss) | $ (224,060,000) | $ (329,668,000) | $ 238,616,000 |
| Company Selected Measure Amount | 3,659,374,000 | 3,094,238,000 | 2,363,567,000 |
| PEO Name | Bruce C. Cozadd | ||
| Measure [Axis]: 1 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Total Revenues | ||
| Measure [Axis]: 2 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Revenue (product- / therapeutic area-specific) | ||
| Measure [Axis]: 3 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Non-GAAP Adjusted Operating Margin | ||
| Measure [Axis]: 4 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Relative TSR | ||
| Measure [Axis]: 5 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | 3 Year Revenue Compound Annual Growth Rate | ||
| Measure [Axis]: 6 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Pipeline Progression | ||
| Measure [Axis]: 7 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Regulatory Advancement | ||
| PEO [Member] | Grant date fair value of awards as reported in the Stock Awards and Option Awards columns in the SCT for applicable fiscal year (FY) [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ (14,873,643) | $ (13,414,116) | $ (10,091,856) |
| PEO [Member] | ASC 718 fair value of awards granted during applicable FY that remain unvested as of applicable FYend, determined as of applicable FYend [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 18,049,908 | 9,742,948 | 17,526,705 |
| PEO [Member] | ASC 718 fair value of awards granted during prior FYs that were outstanding and unvested as of applicable FYend, determined based on change in ASC 718 fair value from prior FYend to applicable FYend [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 3,823,712 | (6,252,113) | 1,921,083 |
| PEO [Member] | ASC 718 fair value of awards granted during prior FYs that vested during applicable FY, determined based on change in ASC 718 fair value from prior FYend to vesting date [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 1,989,410 | (834,792) | (2,331,573) |
| PEO [Member] | Total adjustments [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 8,989,387 | (10,758,073) | 7,024,359 |
| Non-PEO NEO [Member] | Grant date fair value of awards as reported in the Stock Awards and Option Awards columns in the SCT for applicable fiscal year (FY) [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (3,865,859) | (3,505,027) | (3,037,957) |
| Non-PEO NEO [Member] | ASC 718 fair value of awards granted during applicable FY that remain unvested as of applicable FYend, determined as of applicable FYend [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 4,691,422 | 2,802,063 | 5,048,743 |
| Non-PEO NEO [Member] | ASC 718 fair value of awards granted during prior FYs that were outstanding and unvested as of applicable FYend, determined based on change in ASC 718 fair value from prior FYend to applicable FYend [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 996,931 | (1,092,121) | 221,269 |
| Non-PEO NEO [Member] | ASC 718 fair value of awards granted during prior FYs that vested during applicable FY, determined based on change in ASC 718 fair value from prior FYend to vesting date [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 396,177 | (94,465) | (177,703) |
| Non-PEO NEO [Member] | Total adjustments [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ 2,218,671 | $ (1,889,550) | $ 2,054,352 |